Search

Terry William Hermiston

from Mill Valley, CA
Age ~63
Get Report
Also known as:
Terry W Hermiston, Hermiston Hermiston, Terry N
Phone and address:
305 E Strawberry Dr, Mill Valley, CA 94941
(415) 297-7857
Related to:
Christiane Glover, 72Paige Glover, 32Shaniqua Glover, 39John S Babis, 73Julien Vercruyssen, 38Garlan Glover
Connected to:
Michelle L Hermiston, 59Myles A Hermiston, 35Jennifer B Hermitage, 50Michelle L Hermita, 53Akil A Hermitt, 48Andrae R Hermitt, 33Angela K Hermiz, 40Chris F Hermiz, 34Matt Hermiz, 38Mazin S Hermiz, 57

Terry Hermiston Phones & Addresses

  • 305 E Strawberry Dr, Mill Valley, CA 94941 (415) 297-7857
  • 9 Seamast Psge, Corte Madera, CA 94925 (415) 891-8076 (415) 927-0478
  • Saint Louis, MO
  • Iowa City, IA
  • Blue Grass, IA
  • Marina, CA
  • El Dorado, CA

Resumes

Resumes

Terry Hermiston Photo 1

Terry Hermiston

View page
Terry Hermiston Photo 2

Terry Hermiston

View page
Location:
San Francisco Bay Area
Industry:
Pharmaceuticals

Publications

Us Patents

Herpes Simplex Virus For Treating Unwanted Hyperproliferative Cell Growth

View page
US Patent:
6660259, Dec 9, 2003
Filed:
Dec 8, 2000
Appl. No.:
09/733807
Inventors:
Sylvie Laquerre - Walnut Creek CA
Terry Hermiston - Corte Madera CA
Assignee:
Onyx Pharmaceuticals, Inc. - Richmond CA
International Classification:
A01N 6300
US Classification:
424 932, 4353201, 435325, 435 9141, 435 691
Abstract:
The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is cytopathic to susceptible hyperproliferative cells, such as neoplastic cells. Preferably, the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.

Herpes Simplex Virus-1 Glycoprotein C Mutants For Treating Unwanted Hyperproliferative Cell Growth

View page
US Patent:
6723316, Apr 20, 2004
Filed:
Dec 18, 2000
Appl. No.:
09/741127
Inventors:
Sylvie Laquerre - Danville CA
Terry Hermiston - Corte Madera CA
Assignee:
Onyx Pharmaceuticals, Inc. - Richmond CA
International Classification:
A61K 3576
US Classification:
424 932, 424 936, 4241991, 4242051, 4242311, 4352351
Abstract:
The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex virus, which is cytopathic to susceptible target cells, such as neoplastic cells. Preferably, the virus does not produce a functionally active wild-type gC polypeptide coded for the UL44 gene.

Adenovirus E1B Shuttle Vectors

View page
US Patent:
6764674, Jul 20, 2004
Filed:
Dec 27, 1999
Appl. No.:
09/472691
Inventors:
Terry Hermiston - Corte Madera CA
Julie Nye - Berkeley CA
Assignee:
Onyx Pharmaceuticals Inc. - Richmond CA
International Classification:
A01N 6300
US Classification:
424 932, 4353201, 435325, 435455, 4352351, 435471, 435358, 435367, 435365, 435456
Abstract:
Provided are replication competent, recombinant adenovirus vectors containing mutations in the E1B region which permit the easy deletion of a gene or genes therein, and optionally the substitution therefore of a heterologous gene that substantially exhibits the temporal expression pattern of the E1b region gene(s) deleted. Such vectors have applications for the treatment of disease, and preferably for the treatment of neoplastic disease.

Oncolytic Adenovirus

View page
US Patent:
7001596, Feb 21, 2006
Filed:
Nov 14, 2000
Appl. No.:
09/714409
Inventors:
Leisa Johnson - Lafayette CA, US
Ali Fattaey - San Francisco CA, US
Terry Hermiston - Corte Madera CA, US
Assignee:
Onyx Pharmaceuticals, Inc. - Emeryville CA
International Classification:
A61K 48/00
C12N 15/00
C12N 15/63
US Classification:
424 932, 4353201
Abstract:
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.

Oncolytic Adenovirus

View page
US Patent:
7078030, Jul 18, 2006
Filed:
Dec 11, 2003
Appl. No.:
10/733674
Inventors:
Leisa Johnson - Richmond CA, US
Ali Fattaey - Oakland CA, US
Terry Hermiston - Corte Madera CA, US
Jerry Yuqiao Shen - Orinda CA, US
Sylvie Laquerre - Conshohocken PA, US
Assignee:
Onyx Pharmaceuticals, Inc - Emeryville CA
International Classification:
A61K 48/00
C12N 15/00
C12N 15/63
C12N 5/00
C12N 15/86
US Classification:
424 932, 4353201, 435325, 435457
Abstract:
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.

Oncolytic Adenovirus

View page
US Patent:
7396679, Jul 8, 2008
Filed:
Nov 25, 2002
Appl. No.:
10/303598
Inventors:
Leisa Johnson - Lafayette CA, US
Ali Fattaey - San Francisco CA, US
Terry Hermiston - Corte Madera CA, US
Yuqiao Shen - Orinda CA, US
Sylvie Laquerre - Conshohocken PA, US
Assignee:
Onyx Pharmaceuticals, Inc. - Emeryville CA
International Classification:
C12N 15/00
US Classification:
4353201
Abstract:
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.

Chimeric Adenoviruses For Use In Cancer Treatment

View page
US Patent:
7510868, Mar 31, 2009
Filed:
May 24, 2005
Appl. No.:
11/136912
Inventors:
Paul Harden - Brentwood CA, US
Terry Hermiston - Corte Madera CA, US
Irene Kuhn - Richmond CA, US
International Classification:
C12N 15/63
A61K 35/00
US Classification:
4353201, 435 911, 435 914, 435 9142, 536 231
Abstract:
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.

Generation Of Replication Competent Viruses For Therapeutic Use

View page
US Patent:
7550296, Jun 23, 2009
Filed:
Nov 28, 2005
Appl. No.:
11/288821
Inventors:
Terry Hermiston - Corte Madera CA, US
Fang Jin - Danville CA, US
Peter Kretschmer - San Francisco CA, US
Assignee:
Bayer Schering Pharma AG - Berlin
International Classification:
A61K 39/17
A61K 39/205
A61K 39/00
A61K 39/285
A61K 39/23
C12N 15/64
C12N 15/74
C07H 21/02
A61K 39/116
US Classification:
435473, 435 9141, 536 231, 4242141, 4242241, 4242291, 4242321, 4242331
Abstract:
The present invention relates to the generation of replication-competent viruses having therapeutic utility. The replication-competent viruses of the invention can express proteins useful in the treatment of disease.
Control profile
Terry William Hermiston from Mill Valley, CA, age ~63 Get Report